ArticleHead & neck2025
Predictive Factors of Malignancy in Cervical Paragangliomas: A Retrospective Study.
Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictive Factors of Malignancy in Cervical Paragangliomas: A Retrospective Study.Head & neck · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly predictive factors of metastatic cervical paragangliomas (cPG) are lacking.
methodsThis multicenter retrospective study included patients with at least one cPG. Metastatic cPG were defined by the histological presence of lymph node metastases or distant metastases. Clinical, radiological, intraoperative, histological, and mutational status characteristics were collected. Predictive factors of metastatic cPG were searched using logistic regression.
resultsSixty-seven patients were included, corresponding to 86 cPG; 12.8% of these were metastatic. The seven newly identified risk factors were: presence of necrosis (OR = 12.36, 95% CI: [3.03-55.66]), extracapsular extension (OR = 33.42, 95% CI: [2.48-4752.00]), and pathological lymph nodes (OR = 25.00, 95% CI: [3.96-276.07]) on morphological imaging (MRI and/or CT); heterogeneous tumor uptake (OR = 15.5, 95% CI: [2.31-143.68]) and abnormal lymph node uptake (OR = 16.5, 95% CI: [2.04-174.94]) on functional imaging (FDG-PET-CT); invasion of adjacent tissues (OR = 34.63, 95% CI: [3.82-4602.65]) and sacrifice of noble structures (OR = 75.9, 95% CI: [7.99-10230.73]) in patients who underwent surgery.
conclusionThese risk factors could be combined to promptly identify aggressive cPG and adapt therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.